CD160 and hepatocellular carcinoma: Importantly, already on day 7 after therapeutic vaccination with LmAIO in HCC we detected a significant reduction of PD-1, CD160, LAG3, and 4-1BBL on CD4/CD8 T cells in blood (Supplementary Fig. S8D-F).